Search results for " oligos" in Articles / App Notes
Article
Ready for a strong start in oligo manufacturing?
Or are you already manufacturing your own oligos but are running into challenges? If so, we can help.
Fill in the form to discuss your needs with one of our specialists
Article
Are you ready to optimize your oligo synthesis?
In this white paper, we share what we learned in our four decades of experience in flow-through synthesis of oligo manufacturing.
Read it now to explore five key areas in your oligonucleotid…
Article
Developing oligonucleotide therapeutics with confidence
In this video, we will look at key considerations for oligo therapeutic developers entering the market, such as scalability, flexibility, regulatory concerns, insource/outsource consideratio…
Article
Get a strong start in oligonucleotide manufacturing
Building on 40 years of experience, Cytiva launched ӒKTA oligosynt™ benchtop oligo synthesizer in 2022. It is the newest member of our oligo synthesizer family – a family of oligo systems that scales…
Article
Transformative Medicines Challenge FDA and Manufacturers
Transformative Medicines Challenge FDA and Manufacturers
New gene therapies and combination products require innovative regulatory approaches.
By Jill Wechsler …
Article
Get to know: oligonucleotide synthesis workflow
This free interactive course introduces you to synthetic oligonucleotides, applications they’re used in, and how they’re synthesized.
Take the course now
Article
Evolving demands of process development services
And, more recently, there has been a high demand for the CDMOs that can handle oligos, peptides, and various complex conjugates. Novel conjugates involving combinations of oligos, peptides, high poten…
Article
Enhancing Resins Addresses Purification Concerns
Now, we start to see a new landscape based on a variety of new modalities such as viral vectors, mRNA, pDNA, cell and gene therapy, and oligos,” he adds.
Ihre notes that a common feature of …
Article
Working With Advanced Therapeutics: You Bring the Idea, We Bring the Map
Plasmids. mRNA. Oligos. Cell and gene therapies. Antibody variants. Vaccines. We all know these advanced therapies hold huge potential. But developing them isn’t straightforward, and fai…
Article
How can you harness the potential of nucleic acid therapeutics?
At Cytiva, the new team is here to support you. We can help you throughout the
development of your manufacturing workflow for oligonucleotides
and the purification of mRNA drug subs…